RKICET-M

RKICET-M is a combination medicine used to provide effective relief from symptoms of allergic rhinitis (hay fever), including sneezing, runny nose, and itchy/watery eyes, and to prevent and treat symptoms of asthma by reducing airway inflammation.

The two active ingredients are Levocetirizine ($\mathbf{5 ext{ mg}}$), which is an antihistamine, and Montelukast ($\mathbf{10 ext{ mg}}$), which is a leukotriene receptor antagonist.

Levocetirizine works by blocking the action of histamine (a chemical released during allergic reactions) at $ ext{H}_1$ receptors. This effectively reduces the symptoms caused by histamine, such as sneezing, itching, and a runny nose.

Montelukast works by blocking the action of leukotrienes, which are natural substances that cause inflammation, swelling, and narrowing of the airways in the lungs and nose. Blocking them helps reduce symptoms like wheezing and shortness of breath.

No. RKICET-M is a maintenance medication used to prevent asthma symptoms and manage chronic allergies. It should not be used to relieve a sudden, acute asthma attack. For acute attacks, patients should use a rescue inhaler as prescribed.

RKICET-M is typically prescribed to be taken once daily, usually in the evening or at bedtime, as directed by your doctor. Taking it at night helps manage symptoms that may worsen overnight or early morning.

Common side effects include drowsiness, sleepiness, headache, dizziness, and dry mouth. Due to the potential for drowsiness, patients should avoid driving or operating heavy machinery after taking it until they know how the medicine affects them.

No. Alcohol consumption is not recommended while taking RKICET-M. Alcohol can significantly increase the sedative effects of Levocetirizine, potentially leading to excessive drowsiness, dizziness, and impaired judgment.

Montelukast has been associated with rare but serious neuropsychiatric events. Patients and caregivers should watch for changes in behavior, including agitation, aggression, depression, sleep disturbances, or suicidal thoughts, and report them immediately.

Patients with kidney impairment may require a dose adjustment for the Levocetirizine component, as it is mainly eliminated by the kidneys. Use caution in patients with severe liver impairment as Montelukast is metabolized there. Always consult your doctor.